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Abstract
Background/Aims—Current staging guidelines for small intestinal neuroendocrine tumors (SI-
NETs) differentiate between the presence (N1) and absence (N0) of lymph node (LN) metastases. 
However, the prognostic significance of the extent of LN involvement remains unknown. In this 
study, we used data from a population-based cancer registry to examine whether involvement of a 
higher number of LNs is associated with worse survival.
Methods—We used the Surveillance, Epidemiology and End Results (SEER) database to 
identify patients with histologically confirmed, surgically resected SI-NETS diagnosed between 
1988 and 2010. Patients were classified into three groups by the lymph node ratio (number of 
positive lymph nodes/number of total lymph nodes examined, LNR): ≤0.20, >0.20–0.5, and >0.5. 
We used the Kaplan Meier method and Cox models to assess NET cancer-specific survival 
differences (up to 10 years from diagnosis) according to LNR status.
Results—We identified 2,984 surgically resected patients with stage IIIb (N1, M0) SI-NETs 
with detailed LN data. More than half of NETs were located in the ileum. Higher LNR was 
significantly associated with worse NET cancer-specific survival (p<0.0001). Ten-year NET-
specific survival was 85%, 77%, and 74% for patients in the ≤0.2, >0.2–0.5, and >0.5 LNR 
groups, respectively. In stratified analyses, higher LNR groups had worse survival only in early 
tumor (T1, T2) disease (p<0.0001).
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Conclusions—Extent of LN involvement provides independent prognostic information in 
patients with LN positive SI-NETs. This information may be used to identify patients at high risk 
of recurrence and inform decisions about use of adjuvant therapy.
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Introduction
The incidence of small intestinal neuroendocrine tumors (SI-NETs) has tripled over the last 
several decades, likely due to increased performance of imaging and endoscopic procedures. 
[1, 2] The clinical course may vary from slowly progressive to highly aggressive disease 
with heterogeneous patient outcomes. This variability poses significant challenges in 
treatment and medical decision-making. Therefore, accurate staging is critical in 
management of SI-NET patients; it informs treatment selection and discussions about 
prognosis and guides eligibility for clinical trials.
In SI-NET patients, the presence of lymph node (LN) involvement is associated with worse 
survival and may have important treatment implications.[3] In both the American Joint 
Committee on Cancer (AJCC) and European Neuroendocrine Tumor Society (ENETS) 
staging classifications, SI-NETs are classified as N0 or N1 disease based on absence or 
presence of lymph node metastases, respectively (Appendix).[4, 5] Ten-year cancer-specific 
survival is 87% for N0 disease, as compared to 77% for N1 cases.[3] However, there is 
considerable survival heterogeneity even among NET patients with N1 disease.[6, 7] While 
not considered in the NET classification, the extent of LN involvement (i.e., the number of 
positive regional nodes) is an established predictor of survival in other cancers.[8–15] 
However, it remains unknown whether this potential prognostic factor provides additional 
information beyond tumor (T) and node (N) status in SI-NETs.
In this study, we used the National Cancer Institute’s Surveillance, Epidemiology and End 
Results (SEER) cancer registry to assess the prognostic impact of the extent of LN 
involvement among patients with SI-NETs. We hypothesized that more extensive LN 
involvement will accurately discriminate patients with worse disease-specific survival.
Materials and Methods
Study Population
We identified patients with SI-NETs (site codes: C170–173; 178, 179; histological codes: 
8240–8250, 8150–8156, and 9091) diagnosed between 1988 and 2010 from the SEER 
database, a national cancer registry that collects information from incident malignancies 
across several areas of the United States.[16] We included all patients 18 years of age or 
older with pathologically confirmed SI-NETs and without a history of other cancers. We 
excluded cases diagnosed at autopsy or on death certificate or cancers with incomplete 
staging information. We further limited the cohort to patients with surgically resected, stage 
IIIb disease (Any T, N1, M0: tumor of any size and depth [T1–T4], no regional lymph node 
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metastasis [N0], no distant metastasis [M0]).[5] We also identified all resected stage I–IIIa 
patients who were used as a reference population.
Demographic data such as gender, age, race/ethnicity and marital status were obtained from 
SEER. T, N and M status was determined based on detailed data provided by SEER on 
primary tumor size, depth of invasion, local extension, lymph node involvement, and 
presence/absence of distant metastases. Using these information, cancer stage was assigned 
according to ENETS and AJCC staging criteria.[4, 5] SEER also includes data regarding use 
of surgery as part of the primary cancer treatment. We categorized type of resection as: 1) 
local resection (surgical code 20); 2) partial or simple resection (surgical code 30); 3) total 
resection (surgical code 40); or 4) debulking surgery (surgical codes 50–60).
The number of positive LNs can be used as a marker for extent of LN involvement. 
However, this feature is confounded by the number of LNs removed during surgery.[17–20] 
This is particularly problematic as no standards exist about the number of LNs that should 
be removed during SI-NET operations. To address this issue, the lymph node ratio (LNR), 
defined as the ratio between the number of positive nodes and the number of LNs removed 
during surgical resection, has been used to in other gastrointestinal cancers.[17, 21–23] 
Based on cutoffs used in prior studies and the distribution of LNR in the study cohort, we 
classified patients into three LNR groups: ≤0.20, >0.2–0.5, and >0.5.
Survival time was calculated as the period from date of diagnosis until death or last follow-
up (December 31, 2010). We used SI-NET-specific survival as the main study outcome in 
order to evaluate differences in cancer prognosis according to LNR categories. Cause of 
death was determined using SEER data abstracted from death certificates. Individuals who 
were alive at last follow-up or who died from non-NET causes were treated as censored 
observations. This study was exempt from IRB review.
Statistical Analysis
We used the t-test and chi square test to compare the distribution of patients’ characteristics 
such as age, sex, race/ethnicity, marital status, tumor site, T status, and type of surgical 
resection according to LNR group. We then constructed Kaplan-Meier curves to estimate SI-
NET-specific survival for each LNR category; the log-rank test was used to compare 
survival between groups. Survival curves were plotted up to ten years after diagnosis to 
assess long-term outcomes of these relatively slowly progressive tumors while avoiding 
estimating survival curves with small number of cases. We repeated the analyses within 
anatomic site strata to assess the association of LNR with SI-survival among jejunoileaI vs. 
duodenal cancers. We also performed stratified analyses by T status. We used Cox 
proportional hazards models to evaluate the association between LNR groups and NET-
specific survival after adjusting for age, sex, race/ethnicity, marital status, T status, and type 
of surgical resection. All analyses were performed using SAS version 9.3 (SAS Institute 
Inc., Cary, NC, USA) using two-sided p values.
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Results
From SEER, we identified 11,464 SI-NETs diagnosed between 1988 and 2010. We 
excluded 2,658 (23%) patients who had other primary cancers and 1,283 (11%) who had 
incomplete staging information (Figure 1). From these, we selected 2,984 surgically resected 
patients with stage IIIb disease who underwent surgical resection and had detailed lymph 
node data. As a control, we also included data from 860 resected patients with N0 disease. 
More than half (60%) of stage IIIb cases were located in the ileum. The median number of 
lymph nodes removed was 10 (interquartile range, 11). Approximately 30%, 39%, and 31% 
of the cohort had a LNR of ≤0.2, >0.2–0.5, and >0.5, respectively. Demographic 
characteristics of study patients according to LNR group, as well as the reference 
population, are shown in Table 1. Patients in the highest LNR group were older (p<0.0001) 
and male (p=0.005). The groups were similar with respect to race/ethnicity (p=0.57) and 
marital status (p=0.28). However, cancers in the jejunum (p<0.0001) and with advanced T 
(T3 or T4) status (p<0.0001) were more common in the highest LNR category. Finally, 
patients in the highest LNR group were more likely to have local and partial surgical 
resections rather than total resection or debulking surgery (p<0.0001).
Kaplan-Meier analysis showed progressively worse disease-specific survival with higher 
LNRs (p<0.0001, Figure 2). Ten-year survival was 85% (95% confidence interval [CI]: 81–
89%), 77% (95% CI: 73–80%), and 74% (95% CI: 69–78%) for patients in the ≤0.2, 0.21–
0.5, and >0.5 LNR groups, respectively. As a comparison, 10-year SI-NET specific survival 
for N0 disease was 85% (95% CI: 81–89%).
Stratified analyses by T status demonstrated progressively worse survival with higher LNR 
in patients with early T (T1, T2; p<0.0001) but not among those with late T status (T3, 
p=0.24; T4, p=0.40) (Figure 3). Among those with early disease, patients with LNR≤0.2 had 
10-year survival of 94.2% (95%CI: 90–98%), as compared to 91.8% (95%CI: 87–96%) for 
LNR of >0.2–0.5 and 82.5% (95% CI: 74–91%) for LNR>0.5. Conversely, there was no 
significant association between LNR and survival in patients with T3 (p=0.24) or T4 
(p=0.40) disease. These findings persisted in stratified analyses among patients with 
jejunoileal or duodenal disease.
Cox analysis also showed a differential effect of LNR status on disease-specific survival, 
according to T status (i.e., a significant interaction between LNR and T status; Table 2). In 
patients with early T (T1, T2) status, the hazards of death was 1.6 (95%CI: 0.72–3.56), 2.29 
(95%CI: 1.10–4.78), 4.52 (95%CI: 2.24–9.12) for those with LNR≤0.2, >0.2–0.5, and >0.5, 
as compared to patients with N0 disease. Conversely, in patients with T3 status, disease-
specific survival in LNR≤0.2 (HR 0.78, 95%CI: 0.18–3.28), >0.2–0.5 (HR 0.91, 95%CI: 
0.22–3.74), or >0.5 (HR 1.00; 95%CI: 0.25–4.07) were not significantly different compared 
to those with N0 disease. Similarly, disease--specific mortality among T4 patients with 
LNR≤0.2 (HR 0.71, 95%CI: 0.16–3.22), LNR >0.2–0.5 (HR 0.98, 95%CI: 0.23–4.16), and 
LNR >0.5 (HR 0.97, 95%CI: 0.23–4.09) was not significantly different as compared to 
patients with N0 disease. These results persisted after adjusting for number of lymph nodes 
removed; there was no significant association between LNR and the number of lymph nodes 
examined.
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Discussion
Accurate staging of NETs is critical for patient management and research. While current 
ENETS/AJCC classifications help in identification of poor prognostic groups, there is still 
considerable heterogeneity in the outcomes of patients within specific categories. In this 
study, we found that the LNR, a readily available measure of the extent of regional LN 
involvement, was an independent predictor of survival among patient with locoregional SI-
NETs. A revised staging system which incorporates this feature may improve 
prognostication of patients with node-positive SI-NETs.
Our findings regarding the importance of the LNR are consistent with studies in other GI 
cancers. Greenstein et al demonstrated in 838 node-positive esophageal carcinoma patients 
that higher LNR was independently associated with worse outcomes.[24] Similarly, other 
studies have demonstrated that LNR is an independent prognostic predictor in patients with 
node-positive gastric and colon cancer.[17] Our study extends these findings to SI-NET 
patients, demonstrating that LNR can be used to differentiate outcomes, beyond that of the 
existing TNM-based classification. Higher LNR disease may reflect tumors with more 
aggressive biology or extensive disease.
Existing clinical, biochemical, and pathologic markers aid clinicians in assessment of extent 
of disease and response to therapy. Clinical factors such as the presence of carcinoid 
syndrome or carcinoid heart disease predict poor prognosis but are only present in a small 
subset of patients with metastatic disease; thus, limiting its utility. Chromogranin A is the 
most frequently used tumor marker in NETs, but is falsely elevated by near-ubiquitous use 
of proton pump inhibitors.[25–30] Tumor grade (as measured by mitotic and Ki67 indices) 
is incorporated into the ENETS and AJCC classifications and has been shown in multiple 
studies to predict prognosis, but is not performed routinely outside of tertiary hospitals or 
specialty NET centers.[4, 5] Moreover, lack of standardization of assays and reporting 
further hinders use in clinical practice. Thus, there is a need for additional prognostic factors 
to provide information to patients and clinicians.
While LNR is only available in patients who undergo surgical resection, it is a simple and 
readily available marker. It is routinely reported as part of pathological staging and could be 
incorporated in revised classifications without additional cost. Importantly, routine use of 
the LNR can have direct clinical implications. For example, patients with high LNR may 
require more aggressive monitoring and treatment. Thus, future trials should assess the 
potential benefit of adjuvant therapy for these high-risk individuals. Additionally, LNR 
information may help in selecting homogenous populations of SI-NET patients to be 
enrolled in clinical trials. Accurate data may also help patient-provider discussions about 
prognosis and facilitate informed patient decision making.
The major strengths of our study were our large sample of SI-NETs and availability of long-
term survival data. Both of these features enabled us to detect differences in outcomes 
among patients with nodal disease, while adjusting for established TNM-based prognostic 
factors. Another strength of this analysis was the use of a population-based sample thus 
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limiting the impact of referral bias. Finally, the detailed LN data available from SEER 
enabled us to study nodal features that are not typically available in other cancer registries.
The major limitation of this study was the lack of available tumor grade information. Both 
the mitotic and Ki67 labeling index are recognized prognostic factors incorporated into the 
ENETS and AJCC classifications.[4, 5] Thus, we were not able to assess whether the LNR 
is an independent predictor of prognosis after controlling for tumor grade. However, most 
SI-NETs demonstrate lower proliferation, suggesting that tumor grade would not be a major 
confounder. Moreover, the data required to calculate LNR is free, while tumor grade poses 
additional costs. Another limitation was that cause of death was abstracted from death 
certificates, thereby introducing potential for misclassification. However, NET-specific 
survival rates in SEER are consistent with those reported in institutional-based studies with 
more detailed information about cause of death.[6] Finally, the accuracy of LNR may be less 
reliable with smaller number of removed lymph nodes; we were also unable to account for 
lymph node involvement at specific locations (eg. mesentery), as this data is not recorded in 
the SEER registry.
In summary, our findings suggest that LNR independently predicts prognosis and can further 
discriminate outcomes in patients with node-positive SI-NETs. More detailed LN data could 
be incorporated into the current staging system to allow for better assessment of prognosis in 
this patient population. In addition, these data suggest that patients with high LNR are at risk 
for worse outcomes and may be considered for more aggressive postoperative therapy.
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Appendix American Joint Committee on Cancer and European 
Neuroendocrine Tumor Society Staging and Grading Classification for 
Small Intestinal Neuroendocrine Tumors
Primary Tumor (T)
Tx: Primary tumor cannot be assessed
T0: No evidence of primary tumor
T1: Tumor invades lamina propria or submucosa and size<=1cm
T2: Tumor invades muscularis propria or size>1cm
T3: Tumor invades through muscularis propria into subserosa or into nonperitonealized tissue
T4: Tumor invades visceral peritoneum (serosa) or other organs or structures
Regional Lymph Nodes (N)
Nx: Regional lymph nodes cannot be assessed
N0: No regional lymph node metastasis
N1: Regional lymph node metastasis
Distant Metastasis (M)
Mx
M0: No distant metastasis
M1: Distant metastasis
Stage
Stage I T1 N0 M0
Stage IIa T2 N0 M0
 IIb T3 N0 M0
Stage IIIa T4 M0 M0
 IIIb Any T N1 M0
Stage IV Any T Any N M1
Grade Mitotic Index (per 10 HPF) Ki-67 Index (%)
G1 <2 <3%
G2 2–20 3–20%
G3 >20 >20%
HPF: High Powered Field
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Figure 1. 
Flow diagram for SI-NET patients included in the study.
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Figure 2. 
Disease-specific survival stratified by LNR status. Disease-specific survival was 
progressively worse with increasing LNR (p<0.0001). There was overlap of survival in 
patients with N0 and lowest LNR status.
Kim et al. Page 10
Neuroendocrinology. Author manuscript; available in PMC 2016 January 05.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Kim et al. Page 11
Neuroendocrinology. Author manuscript; available in PMC 2016 January 05.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 3. 
Figure 3A. In patients with early T (T1, and T2), disease-specific survival was progressively 
worse with increasing LNR (p<0.0001).
Figure 3B. In patients with T3 status, higher LNR was not associated with worse disease-
specific survival.
Figure 3C. In patients with T4 status, higher LNR was not associated with worse disease-
specific survival.
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Table 2
Influence of LNR Status on Risk of Disease-specific Mortality
Disease Status N Reference Hazard Ratio 95% Confidence Interval
T1T2
T1T2, LNR≤0.2 305 T1T2, N0 1.60 0.72–3.56
T1T2, 0.2<LNR≤0.5 261 T1T2, N0 2.29 1.10–4.78
T1T2, LNR>0.5 143 T1T2, N0 4.52 2.24–9.12
T3
T3, LNR≤0.2 417 T3, N0 0.78 0.18–3.28
T3, 0.2<LNR≤0.5 598 T3, N0 0.91 0.22–3.74
T3, LNR>0.5 492 T3, N0 1.00 0.25–4.07
T4
T4, LNR≤0.2 143 T4, N0 0.71 0.16–3.22
T4, 0.2<LNR≤0.5 263 T4, N0 0.98 0.23–4.16
T4, LNR>0.5 261 T4, N0 0.97 0.23–4.09
T: Tumor status; N: Node status; LNR: Lymph Node Ratio
Adjusted for age, sex, marital status, primary tumor site
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